Allogene Therapeutics, Inc. (ALLO)

NASDAQ: ALLO · IEX Real-Time Price · USD
10.80
-0.63 (-5.51%)
At close: Sep 30, 2022 4:00 PM
11.34
+0.54 (5.00%)
After-hours: Sep 30, 2022 5:51 PM EDT
-5.51%
Market Cap 1.55B
Revenue (ttm) 247,000
Net Income (ttm) -307.69M
Shares Out 143.81M
EPS (ttm) -2.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,358,079
Open 10.29
Previous Close 11.43
Day's Range 10.18 - 11.08
52-Week Range 6.43 - 25.00
Beta 0.52
Analysts Buy
Price Target 27.86 (+158.0%)
Earnings Date Nov 2, 2022

About ALLO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin ... [Read more...]

Industry Biotechnology
IPO Date Oct 11, 2018
Employees 344
Stock Exchange NASDAQ
Ticker Symbol ALLO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is 27.86, which is an increase of 157.96% from the latest price.

Price Target
$27.86
(157.96% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

1 week ago - GlobeNewsWire

Allogene Therapeutics (ALLO) Down 10.9% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well

Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.

1 month ago - Zacks Investment Research

Allogene Therapeutics (ALLO) Reports Q2 Loss, Tops Revenue Estimates

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 14.75% and 7.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Allogene Therapeutics Reports Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

1 month ago - GlobeNewsWire

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

1 month ago - GlobeNewsWire

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

2 months ago - GlobeNewsWire

Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

2 months ago - GlobeNewsWire

Allogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last?

Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

3 months ago - Zacks Investment Research

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501...

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

3 months ago - GlobeNewsWire

Why Is Allogene Therapeutics (ALLO) Down 14.9% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of D...

SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T...

4 months ago - GlobeNewsWire

Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Bus...

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T...

4 months ago - GlobeNewsWire

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progresses Well

Allogene's (ALLO) first-quarter earnings beat estimates. Upon removal of the FDA's clinical hold on its AlloCAR T candidates, ALLO continues to move forward with its pipeline.

4 months ago - Zacks Investment Research

Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 5.08% and 39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Allogene Therapeutics Reports First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T...

4 months ago - GlobeNewsWire

Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

5 months ago - GlobeNewsWire

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate...

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

5 months ago - GlobeNewsWire

Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

5 months ago - GlobeNewsWire

Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

5 months ago - GlobeNewsWire

Up 18% In A Month, Will Allogene Therapeutics Stock See Higher Levels?

The stock price of Allogene Therapeutics, a biotechnology company focused on T-cell therapies for solid tumors, has seen an 18% rise over the last month, white it's down 38% YTD. The stock price over th...

5 months ago - Forbes

Why Is Allogene Therapeutics (ALLO) Up 7.4% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic ...

SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

6 months ago - GlobeNewsWire

Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?

Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price in...

6 months ago - Zacks Investment Research

Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs

With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.

6 months ago - Zacks Investment Research